By-Band-Sleeve trial: RYGB betters LSG on weight loss and quality-of-life outcomes
Outcomes from the By-Band-Sleeve trial has confirmed the safety and effectiveness of bariatric and metabolic surgery (BMS) and that...
top of page
Headlines
By-Band-Sleeve trial: RYGB betters LSG on weight loss and quality-of-life outcomes
Outcomes from the By-Band-Sleeve trial has confirmed the safety and effectiveness of bariatric and metabolic surgery (BMS) and that...
Research
WL Gore launches Gore SYNECOR preperitoneal biomaterial in Europe, the Middle East and South Africa
WL Gore & Associates (Gore) has announced that GORE SYNECOR Preperitoneal Biomaterial is now available in Europe, Middle East and South...
Journal Watch 2/3/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Early data shows Revita has potential to prevent weight regain after GLP-1 discontinuation
Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...
ENDRA reveals enhanced Strategy to enable the early detection and management of metabolic diseases facilitated by emerging GLP-1 therapies
ENDRA Life Sciences has revealed a new strategic direction to develop and deploy its Thermo-Acoustic Enhanced UltraSound system (TAEUS)...
SUMMIT: Tirzepatide benefits people with obesity, kidney disease and heart failure
Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection...
By-Band-Sleeve trial: RYGB betters LSG on weight loss and quality-of-life outcomes
Outcomes from the By-Band-Sleeve trial has confirmed the safety and effectiveness of bariatric and metabolic surgery (BMS) and that...
Researcher 2 Researcher and Bariatric News - The Podcasts
Spend an engaging hour with Researcher 2 Researcher and Bariatric News as we explore a range of topics in Bariatric and Metabolic...
SOUL trial: Oral semaglutide 14 mg demonstrated superior reduction in risk of CV events
e full results from the SOUL cardiovascular outcomes trial, investigating the effects of Rybelsus (semaglutide) tablets 14 mg on reducing...
Analysis of SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV events
Analysis of the SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV...
Expanding access to anti-obesity medications delivers 13% return on investment for society
A USC Schaeffer Center white paper entitled, ‘Lifetime Social Returns From Expanding Access to Anti-Obesity Medication’, finds expanded...
First patient dosed in study of Corbus’ next-generation CB1 Inverse Agonist CRB-913 for the treatment of obesity
The first patient has been dosed in Corbus Pharmaceuticals in the single ascending dose/multiple ascending dose (SAD/MAD) portion of the...
Vivani issues positive preclinical weight loss data for NPM-139 semaglutide implant
Vivani Medical has announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic...
Industry
All caught up?
New: Directory
Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.
Events
Tweets
bottom of page